Member Info for Marty130

I did mention this would drop tp 2p, a while back. Was their intention from the outset, in order for the BoD/family members maximise their holding. Watch for director dealings in the coming weeks and months. A sign they expect the SP to rise, and value adding news is forthcoming.

Https://yorkshireherald.co.uk/genflow-biosciences-share-price/

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has cleared a key hurdle in its bid to patent a gene therapy targeting ageing, after the European Patent Office (EPO) confirmed that claims in one of the company's core applications are patentable.

The development means Genflow’s application, covering a variant of the SIRT6 gene, has now entered the final pre-grant stage, a significant step in securing full patent protection across Europe.

While the patent has not yet been formally granted, the application has been published in the EPO Bulletin and now enjoys provisional protection in participating member states.

This allows Genflow to enforce its rights in those countries, subject to local validation processes.

Dr Eric Leire, Genflow’s chief executive, said: “The publication by the EPO represents a major validation of our scientific innovation and long-term IP strategy.

"Securing formal European recognition for our patent moves us closer to full protection of our longevity gene therapy platform and strengthens our strategic position for future partnerships and funding opportunities.”

The company will need to update the patent’s description to bring it into line with the approved claims before the EPO issues a formal intention to grant.

Founded in 2020 and listed in London, Genflow is developing therapies aimed at slowing the biological ageing process, with a view to extending both lifespan and healthspan, the number of years lived in good health.

Its lead compound, GF-1002, delivers a variant of the SIRT6 gene found in centenarians, a group of people who live to 100 or beyond.

The gene is being tested in a 12-month trial in older dogs, which began earlier this year.

The company also plans to explore GF-1002’s potential in treating MASH, or Metabolic dysfunction-associated steatohepatitis, a common liver disease for which there are currently no approved treatments.

The European patent progress could also help position Genflow to access potential grant funding from the European Union and bolster its negotiating hand in discussions with larger pharmaceutical partners.

The Broader Longevity Market: A Rising Tide for GENF?

Genflow does not operate in a vacuum. The global longevity biotech market is projected to grow from $21 billion in 2025 to over $23 billion in 2026. This growth reflects a structural shift in healthcare toward preventive “healthspan” management. As institutional investors move into this space, they seek established players with clinical data. Genflow’s recent success in animal trials makes it a prime candidate for acquisition or major partnership by “Big Pharma” The AVCT Share Price companies looking to enter the longevity sector.

Https://yorkshireherald.co.uk/genflow-biosciences-share-price/

Https://www.theaic.co.uk/aic/news/industry-news/ma-wave-continues-for-international-biotech-as-day-one-finds-buyer

Merger & Acquisition (M&A) Activity: Patent ownership makes a biotech company a more attractive acquisition target for big pharma companies seeking to fill their own "patent cliff" revenue gaps.

Share prices after biotech receives patents

+10

Biotech share prices often rise immediately following the announcement of a key patent, as it validates the company's innovation, strengthens its competitive edge, and signals a potential monopoly period that can lead to increased future cash flows. However, the long-term impact on the share price depends on the company's ability to turn that patent into a commercialized product, especially since 90% of public biotech companies are often pre-revenue

8p minimum.

It certainly could do with a lift, as volumes are pitiful.

Look at genflow!!

Back down to 1 or 2p as i was predicting.. Huge fund raise...

I would put the trades down to a fund buying in, building a position, presumably after they pass 3/5% an rns will reveal all.

I've read numerous books on trading in the modern age, have never come across this before. Yes funds can pile in buying thousands of trades, which can push sp up, and sell, making on the way up and making on shorting the stock, market manipulation, and yes they use algorithms to aid in their efforts, but there is always a human factor..

They are not allowed to buy their own stock without informing the market..

Could be..

My research on him is limited. Thanks, I new have more confidence.

A damp squib of sorts apponting GB.. He hasn't any experience in creating multimillion pound companies.

Gad Berdugo added: "I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and help drive Genflow, and deliver long-term value for shareholders and patients."

Biotech share prices often experience a significant re-rating following patent approval, particularly when the patent secures market exclusivity for a blockbuster drug or validates a key intellectual property (IP) asset for a smaller company.

Patent Approval Dynamics

Validation of Assets: Patent approvals, especially for crucial assets, are viewed positively, reinforcing the company's valuation and market position.

Re-rating Drivers: A, positive court ruling that a patent is "Valid and Infringed" can lead to an average gain in firm value of approximately 0.7%, while a loss can have a more severe negative impact.

Short-term Volatility: While approvals are inherently good, the immediate re-rating can be volatile based on whether the patent approval was already priced in ("sell-the-news") or if it provides unexpected, significant revenue protection.